Results 141 to 150 of about 5,080 (193)

The social value of lecanemab for patients with early Alzheimer's disease in Japan. [PDF]

J Alzheimers Dis
Igarashi A, Azuma-Kasai M, Tani M, Utsumi T, Shibahara H, Inoue S, Rothwell S, Kamanaka G, Sakata Y, Hiyoshi H, Tomita K.   +10 more
europepmc   +1 more source

Baseline plasma C1q and C3 as potential biomarkers for lecanemab efficacy and ARIA risk in early Alzheimer's disease. [PDF]

Alzheimers Dement (N Y)
Byeon G, Lee JW, Kim S, Um YH, Wang SM, Ha S, Park SY, Shin I, Jang J, Lee CU, Lim HK, Kang DW.   +11 more
europepmc   +1 more source

Are lecanemab and donanemab disease‐modifying therapies?

Alzheimer's & Dementia
Timothy Daly, Kasper P. Kepp, Bruno P. Imbimbo   +2 more
openaire   +2 more sources

Safety and short-term outcomes of lecanemab for Alzheimer's disease in China: a multicentre study. [PDF]

Brain
Li LL, Wang RZ, Wang Z, Hu H, Xu W, Zhu L, Sun Y, Chen KL, Chen SF, He XY, Yuan MY, Huang YY, Liu XY, Liu P, Ye QY, Wang J, Ju ZZ, Zhang W, Hu B, Guo Y, Cao XY, Li YX, Zuo CT, Cheng W, Jiang T, Tan L, Chen XC, Zhao QH, Cui M, Peng GP, Xin JW, Yu JT.   +31 more
europepmc   +1 more source

Performing multiple biomarker tests delays initiation of amyloid-targeting treatments. [PDF]

Alzheimers Dement (Amst)
Hofmann A, Paczynski M, Ponisio MR, Saef B, Roberts JP, Powell WJB, Gupta A, Oh I, Hofford M, Posey Z, Aldinger M, Benzinger TLS, Morris JC, Snider BJ, Schindler SE.   +14 more
europepmc   +1 more source

A Narrative Review of Amyloid-β Monoclonal Antibodies for Alzheimer Disease: How Amyloid Species Engagement May Affect Clinical Outcomes. [PDF]

Neurologist
Caselli RJ, Geldmacher DS, Schilling TB.
europepmc   +1 more source

From Target Engagement to Treatment Governance: The Evolving Role of Amyloid PET in Anti-Amyloid Therapy. [PDF]

Lancet Reg Health Eur
Filippi M, Cecchetti G, Ghirelli A, Spinelli EG, Rugarli G, Pisano S, Samanes Gajate AM, Chiti A, Agosta F.   +8 more
europepmc   +1 more source

Value-based prices of emerging disease-modifying therapies for Alzheimer's disease in 174 countries: a cost-effectiveness and threshold analysis. [PDF]

Alzheimers Dement
Hoang MT, Kahn JG, Saha S, Trépel D.
europepmc   +1 more source

Lecanemab Reduces Neuropsychiatric Symptoms and Related Regional Brain Amyloid Load in Early Alzheimer's Disease: A Preliminary Prospective Study. [PDF]

CNS Neurosci Ther
Chang Y, Li H, Liu X, Li X, Liu J, Song J, Fu H, Xu X, Wang Y, Wang Q, Ren N, Chen J, Deng X, Zhang X, Zuo L, Zhou B, Sun X, Li Z, Cao Y, Wu R, Jia J, Qian H, Wang R.   +22 more
europepmc   +1 more source